Janux Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 58.29 million compared to USD 63.06 million a year ago. Basic loss per share from continuing operations was USD 1.32 compared to USD 1.52 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.99 USD | +1.89% | -4.00% | +347.25% |
05-08 | Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating | MT |
05-08 | Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+347.25% | 2.49B | |
+41.79% | 54.04B | |
+46.11% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |
- Stock Market
- Equities
- JANX Stock
- News Janux Therapeutics, Inc.
- Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023